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Objective: To determine the effect of changing from
etanercept or methotrexate monotherapy to etanercept
plus methotrexate combination therapy on radiographic
progression in rheumatoid arthritis (RA) patients.
Methods: Patients enrolled in this 1-year open-label
study previously completed a 3-year blinded study in
which they received methotrexate or etanercept mono-
therapy or the combination of both. All patients received
the combination of etanercept 25 mg subcutaneously
twice weekly plus oral methotrexate up to 20 mg/week.
The primary radiographic endpoint was a change in
modified total Sharp score (TSS), as assessed by blinded
readers.
Results: At baseline, patients previously receiving
methotrexate monotherapy (etanercept-added, n = 52)
or etanercept monotherapy (methotrexate-added,
n = 68) had moderate disease activity levels (mean
disease activity score (DAS) of 2.6 and 2.5, respectively),
whereas patients previously receiving combination ther-
apy (n = 90) had a low disease activity level (mean
DAS of 2.0). The addition of etanercept to methotrexate
monotherapy resulted in a significant reduction in
radiographic progression (p,0.05). Mean TSS changes in
the previous year versus the current year were +1.79
versus +0.25 for the etanercept-added group (p,0.05);
+0.51 versus 20.18 for the methotrexate-added group
(NS) and +0.42 versus +0.24 for the combination group
(NS).
Conclusion: In these RA patients with on average
moderate disease activity despite previous methotrexate
monotherapy, combination treatment with etanercept and
methotrexate inhibited radiographic progression and
improved radiographic outcomes. These data, in con-
junction with the previously published clinical data,
support the use of combination therapy in RA patients
with moderate disease activity.
Rheumatoid arthritis (RA) is a chronic, systemic,
inflammatory autoimmune disease, which occurs
in approximately 1% of the adult population in
western countries,1 2 and is associated with pro-
gressive joint destruction, functional disability and
increased mortality.3–8 Several studies have shown
a rapid rate of progression in erosion and cartilage
destruction in the early years of the disease that
appeared to decrease in later disease.7 9–13 In a 3-year
study in patients with early RA, van der Heijde
et al10 observed an initial rate of radiographic
progression of 14 standard units (SU) in total
Sharp score (TSS), out of a maximum of 448 SU, in
the first year and a progression to 9 SU in the
subsequent 2 years during treatment with conven-
tional disease-modifying antirheumatic drugs
(DMARD). Moderate loss of functional ability
may develop in half of affected individuals within
2 years of RA diagnosis.8 Therefore, treatment of
RA with effective therapy early in the disease
course is recommended, with the goal of long-term
remission and prevention or limitation of joint
damage and functional loss.14
Among the DMARD currently used in RA,
methotrexate is often selected first, particularly
for patients with more active disease, because
randomised, controlled clinical trials have estab-
lished its efficacy in improving symptoms and
function and in slowing the progression of joint
erosion.14 However, several trials have shown that
joint destruction continues even with the use of
high-dose methotrexate15–20 as well as sequential
DMARD monotherapy or step-up combination
DMARD therapy.21 In addition, the majority of
patients discontinue most conventional DMARD
regimens within 2 years, most often because of
insufficient efficacy or intolerability.22 Biological
drugs that selectively block tumour necrosis factor
(TNF), a pro-inflammatory cytokine involved in
the pathogenesis of RA,23 have become an impor-
tant therapeutic option in RA. Clinical trial data
have demonstrated that the use of TNF antago-
nists, alone or in combination with methotrexate,
is effective in improving both clinical and radio-
graphic outcomes in patients with RA.16–20 24–28
Although these newer antirheumatic medications
and regimens are highly effective, there is still more
to learn about which patients should be treated
with these therapies.
In this study, we provide the radiographic results
of a 1-year study in which patients with RA who
previously completed 3 years of a blinded therapy
with methotrexate or etanercept alone or a
combination of both all received treatment with
the combination of etanercept and methotrexate
for 1 year. The results of the clinical outcomes25
demonstrated that patients with partial response
to long-term monotherapy and a mean moderate
disease activity level can obtain a greater benefit
with combination therapy and that patients can
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sustain the benefit or continue to show improvement through
4 years of combination therapy.
PATIENTS AND METHODS
A detailed description of the study design is provided else-
where.25 In brief, RA patients who completed 3 years of
treatment with methotrexate, etanercept, or a combination of
both in a double-blind study18 29 30 were eligible to enroll in the
current study. All enrolled patients received both open-label
etanercept 25 mg subcutaneously twice weekly and oral
methotrexate at individualised doses up to 20 mg/week.
Radiographic evaluations were performed at baseline of the
current study and at year 1.
The study protocol and an informed consent form received
approval by the independent ethics committee or institutional
review board at each institution before study initiation. All
participating patients provided written informed consent before
enrollment in the study. The study was conducted in
accordance with the ethical principles of the Declaration of
Helsinki.
Radiographic assessments
Radiographs of the hands, wrists and forefeet were taken at the
baseline visit (post 3-year, double-blinded portion of the study)
and at week 52 or the final study visit. In addition, the films
from years 2 and 3 of the prior double-blind study were re-
analysed, allowing evaluation of changes in radiographic
progression before and after the initiation of combination
therapy in patients receiving previous monotherapy and with
the continuation of combination therapy in those receiving
previous combination therapy. The primary radiographic end-
point was the change from baseline in the van der Heijde-
modified TSS,31 which was calculated from baseline to year 1 or
the final study visit for all patients with valid radiographic data.
Other radiographic assessments included changes from baseline
to year 1 in erosion and joint space narrowing (JSN) scores;
differences in annualised rates of change in modified TSS, along
with erosion and JSN scores, from the year before the current
study (when patients were receiving blinded monotherapy or
combination therapy) and the current 1-year study period; and
the proportion of patients with radiographic non-progression,
defined as modified TSS change of 0.5 or less and as modified
TSS change of 0.0 or less. The changes from baseline in modified
TSS were presented in cumulative probability plots to allow
visualisation of all radiographic data over the 1-year period.
Frequency distributions of the observed cumulative proportion,
by which scores were ranked from lowest to highest by
treatment group and expressed as a cumulative percentage of
all scores, were plotted against the actual change in modified
TSS.
Radiographs from each patient were acquired according to
procedures prepared by Bio-Imaging Technologies (Newtown,
Pennsylvania, USA), which also digitised and archived the
images. Two independent physicians read the digitised image
sets of radiographic films for each patient in random sequence
using a computer-assisted masked reading method. The readers
remained blinded to the treatment groups of the previous 3-year
study and to the order of radiographs throughout the reading
process. An image set was composed of images from three
time points: the final visits of year 2 of the previous double-
blind study and the baseline visit (same as year 3 of the previous
study) and the final visit of the current study. The average
score of the two readers was used in the analyses. To validate
reader reliability, inter-reader and intra-reader variability intra-
class correlations were calculated. Five per cent of images
were read twice and scores from the second reading were
compared with those from the first reading to determine intra-
reader correlations. Status scores on all images from all patients
read by both readers were used to calculate inter-reader
variability.
Figure 1 Patient disposition. ETN,
etanercept; MTX, methotrexate.
Extended report
1114 Ann Rheum Dis 2009;68:1113–1118. doi:10.1136/ard.2008.094375
 group.bmj.com on August 11, 2010 - Published by ard.bmj.comDownloaded from 
Statistical analysis
The number of patients who completed year 3 of the previous
double-blind study (n = 327) determined the sample size in
this study, because only these patients were eligible for
enrollment in the current open-label extension. Changes from
baseline in modified TSS and erosion and JSN scores were
analysed in all enrolled patients who received at least one dose
of study drug and had readable baseline and on-therapy
radiographs for the current 1-year study. For patients who did
not complete the study, radiographs were taken at the final
study visit and radiographic progression was imputed by linear
extrapolation.
Radiographic assessments were analysed using an analysis of
covariance (ANCOVA) model based on the ranks of the average
scores from the two readers, including factors for baseline
modified TSS rank, treatment group and methotrexate use
before the original double-blind study initiation as covariates.
ANCOVA results were accompanied by 95% CI. Radiographic
non-progression (modified TSS change (0.5 and modified TSS
change (0.0) was analysed using a Mantel–Haenszel approach,
with stratification by study centre and prior methotrexate use.
Inter-reader and intra-reader correlation coefficients were
determined by analysis of variance.32
Clinical efficacy and safety analyses were performed using a
modified intention-to-treat approach in which all patients who
were randomly assigned and received at least one dose of study
drug were included. The last-observation-carried-forward
method was used to account for missing data when assessing
clinical endpoints. All tests and confidence intervals were two-
sided at an alpha of 0.05.
RESULTS
Patients and disposition
Of 686 patients randomly assigned in the original double-blind
study,29 327 completed all 3 years of treatment. One hundred of
these patients did not participate in the current study because
they elected not to continue (n = 19) or their site discontinued
participation in the study for non-medical reasons (n = 81),
the most common being investigator lack of interest and
regulatory document submission delays.
Of the 246 patients eligible to participate in this study, 227
patients (92.3%) were enrolled: 96 patients were previously
treated with the combination of etanercept and methotrexate
(combination); 55 patients with methotrexate monotherapy
(etanercept-added); and 76 patients with etanercept monother-
apy (methotrexate-added). Seventeen of the 227 enrolled
patients (7.5%) were excluded from the radiographic inten-
tion-to-treat population (six patients in the combination group,
three patients in the etanercept-added group and eight patients
in the methotrexate-added group) because the required radio-
graphs were not obtained (n = 10) or were unreadable
(n = 7). An additional patient, who received etanercept
monotherapy in the double-blind study, was excluded from
the comparative analyses of radiographic progression between
baseline (year 3 of double-blind treatment) and 1 year of open-
label treatment because valid radiographs were not available
from the original study. A total of 213 patients (93.8%)
completed the 1-year study (fig 1); 209 patients were included
in the radiographic intent-to-treat analysis.
Baseline demographics of the population enrolled in the
current study were similar across treatment groups. Details
have been published previously.18 25 29 30 At baseline of this
study, patients in the combination group had lower disease
activity than those in the other two treatment groups. The
mean disease activity score (DAS) of 2.0 in the combination
group was in the low disease activity range (DAS ,2.4) and
significantly lower (p,0.05) than the mean DAS of 2.6 and 2.5
in the etanercept-added and methotrexate-added groups,
respectively, which were both in the moderate disease activity
range.
Radiographic efficacy
Changes in modified TSS and erosion and JSN scores
For all three treatment groups, the change in modified TSS was
less during the current study on combination therapy than
during the last year in the blinded study. However, only the
addition of etanercept to methotrexate monotherapy resulted in
a statistically significant reduction in radiographic progression
during the year of open-label treatment (+1.79 to +0.25, p,0.05;
fig 2). During treatment with combination etanercept and
methotrexate therapy, all three groups demonstrated a mean
radiographic progression of 0.25 or less. The mean changes in
erosion scores during the last year of the double-blind study
were +0.19, +0.66 and +0.21 for the combination, etanercept-
added, and methotrexate-added groups, respectively. One year
after combination therapy was administered to all patients in
the current study, the erosion scores decreased to +0.06, +0.27
and 0.00, respectively. Similarly for JSN, the scores for the last
year were +0.24, +1.12, +0.30 for the combination, etanercept-
added, and methotrexate-added groups, respectively, which
improved to +0.18, 20.02, 20.18 after treatment with
combination therapy for 1 year.
Cumulative probabilities of individual changes from baseline
in modified TSS during the 1-year period of the study, during
which all patients received combination therapy with etaner-
cept and methotrexate, are shown in fig 3. The majority of
patients in all groups showed no progression or negative scores.
The etanercept-added group included the highest percentage of
patients with progression.
Radiographic non-progression
The percentage of patients with no progression of joint damage,
when defined as modified TSS change of 0.5 or less, increased
Figure 2 Mean change in modified total Sharp score (TSS) by
treatment group from year 2 to year 3 of the previous double-blind study
and from baseline to year 1 of the current study. ETN, etanercept; MTX,
methotrexate.
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significantly for the etanercept-added group from year 3 to the
current study (from 51.9% to 69.2%, p,0.05; fig 4); the other
groups also demonstrated higher rates of non-progression in the
study, but these were not significant. The results were similar
when the radiographic non-progression definition was based on
a modified TSS change of 0.0 or less. The etanercept-added
group improved from 44.2% to 67.3% (p,0.05); the methotrex-
ate-added group improved from 62.7% to 77.9% (p = NS) and
the combination group improved from 68.9% to 73.3%
(p = NS).
Inter and intra-reader correlation
Inter-reader correlation coefficients on erosion, JSN and TSS
status scores at year 2 and year 3 ranged from 0.79 to 0.93;
corresponding intra-reader correlation coefficients on radiologi-
cal scoring data were 0.94 to 0.98.
DISCUSSION
The purpose of the current study was to determine whether
previous monotherapy responders with a residual moderate
disease activity level on average after long-term methotrexate or
etanercept monotherapy would achieve further clinical and
radiographic benefit from combination therapy with these
agents. As reported elsewhere,25 the combination group had low
disease activity at the baseline of this study, whereas the
etanercept-added and methotrexate-added groups had moderate
disease activity. At week 52, all three treatment groups showed
low disease activity (DAS ,2.4) on average, with DAS of 1.9,
1.9 and 2.2 reported in the combination, etanercept-added and
methotrexate-added groups, respectively (p,0.05 within
group). Patients in the etanercept-added group achieved the
greatest increase in DAS remission rates from the extension
study baseline to week 52 (23.6% to 41.8%, p,0.01); patients in
the combination (37.6% to 50.0%, p,0.01) and methotrexate-
added (26.7% to 36.8%, p = NS) groups also demonstrated
improvements. In addition, during the 52-week extension,
combination treatment was associated with a favourable safety
profile; no new unexpected safety signals or toxicities were
observed. No cases of tuberculosis, opportunistic infections,
systemic lupus erythematosus, or central demyelinating dis-
orders occurred and serious infections were uncommon.25
The results reported here indicate that 1 year of combination
therapy can also provide additional radiographic improvement
for patients with average moderate disease activity after 3 years
of monotherapy. Moreover, continuation of combination
therapy after 3 years of this regimen sustained or improved
the prevention of radiographic progression from year 3 of the
double-blind study to the end of the current 1-year study.
Previous studies have shown that clinically relevant progression
of joint damage can occur in patients with RA achieving
persistent clinical remission with conventional DMARD ther-
apy.33 34 Similarly, in an analysis of the 3-year Trial of Etanercept
and Methotrexate with Radiographic and Patient Outcomes
(TEMPO) data, mean radiographic progression rates continued
to increase, even in patients treated with methotrexate alone
who were in clinical remission or who had very low disease
activity.35 Overall, however, increased radiographic progression
was linked to increasing systemic inflammatory activity in
those receiving methotrexate monotherapy. In contrast,
patients treated with the combination of etanercept and
methotrexate demonstrated inhibition of joint destruction
independent of inflammatory activity. Moreover, even in
patients with the lowest level of inflammation, progression of
joint damage with combination therapy was at a significantly
lower level than that with methotrexate alone. The radio-
graphic progression that occurs despite good clinical response
may support the need for more aggressive therapy than
conventional DMARD. A more intensive therapeutic strategy
could be considered to extend the standard of care beyond the
control of disease activity to include radiographic non-progres-
sion and prevention of functional loss. The gain in long-term
outcome in terms of function, ability to work and participation
should be weighed against the extra costs involved in such a
strategy.
The TEMPO study was the first to demonstrate that the
combination of etanercept and methotrexate inhibits radio-
graphic progression more than methotrexate or etanercept
monotherapy. Although patients receiving etanercept and
methotrexate monotherapies showed similar clinical improve-
ment in both the second and third years of the double-blind
Figure 3 Probability plots of individual changes from baseline in
modified total Sharp score (TSS) during the current 1-year study for the
combination, etanercept (ETN)-added and methotrexate (MTX)-added
groups. Figure 4 Percentage of patients by treatment group with no
radiographic progression, defined as change in modified total Sharp
score (TSS) (0.5, from year 2 to year 3 of the previous double-blind
study and from baseline to year 1 of the current study. ETN, etanercept;
MTX, methotrexate.
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study, those receiving methotrexate monotherapy had greater
increases in radiographic damage during these intervals.18 30 In
patients who received the methotrexate-only regimen for
3 years, adding etanercept for 1 year in this study significantly
reduced the rate of radiographic progression; patients who had
received etanercept monotherapy or combination therapy for
3 years demonstrated some reductions in radiographic progres-
sion during this year of combination therapy, although these
changes were not significant. Whereas the rate of radiographic
non-progression was significantly increased with the addition of
etanercept in the methotrexate monotherapy group (69%), it
ultimately did not reach the levels achieved in the groups that
previously received either etanercept alone or in combination
(79% and 81%, respectively). The observed difference in
frequency of non-progression indicates that earlier use of
combination etanercept–methotrexate treatment may provide
a meaningful reduction in joint destruction compared with
methotrexate alone.
Despite the minimal radiographic progression in all groups
with combination therapy, treating patients for 3 years with
methotrexate monotherapy before adding etanercept may have
already led to some irreversible joint damage. For the
methotrexate monotherapy group that added etanercept in this
study, the mean radiographic progression was only +0.25
modified TSS units. However, during the last year of
methotrexate monotherapy, the mean progression was +1.79
and during the first 2 years of methotrexate monotherapy in
TEMPO, the mean progression was +3.34.30 In contrast, the
combination group demonstrated a mean progression of +0.24
in this study, compared with +0.42 in the last year and 20.56 in
the first 2 years of TEMPO.30 The composite mean progression
after 3 years of treatment with methotrexate alone was +5.13,
compared with +0.10 after 4 years of combination treatment
with etanercept plus methotrexate. Although these data
represent mean values for the two groups, it may be worth
noting that, in individual patients, progression in modified TSS
of more than 5 units with methotrexate monotherapy over
3 years represents a clinically important progression based on
international expert panel findings.36
These radiographic results augment the previously reported
clinical findings,25 showing that patients who have improved
from a mean of severe to moderate disease activity with
methotrexate treatment continue to experience progressive
radiographic damage that can be blocked by the addition of
etanercept. Combination treatment with etanercept plus
methotrexate provided enhanced protection against joint
damage in patients with RA who had moderate disease activity
despite monotherapy with either agent. Although all three
groups showed some improvement, this benefit was particularly
pronounced when etanercept was added to methotrexate
monotherapy. The radiographic improvements achieved by
patients treated with combination therapy for 3 years in the
original double-blind study were sustained or improved during
the fourth year of open-label treatment. The results of this
study support the use of combination therapy with etanercept
and methotrexate in patients with moderate disease on
methotrexate monotherapy and suggest that earlier combina-
tion therapy could be considered in these patients.
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